NDC 66658-510

GAMIFANT

(emapalumab-lzsg)

GAMIFANT is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Swedish Orphan Biovitrum Ab (publ). The primary component is Emapalumab.

• Product ID: 66658-510_5a77518a-477d-47fa-a0d4-ce986eb7e964
• NDC: 66658-510
• Product Type: Human Prescription Drug
• Proprietary Name: GAMIFANT
• Generic Name: (emapalumab-lzsg)
• Dosage Form: Injection
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2020-06-26
• Marketing Category: BLA / BLA
• Application Number: BLA761107
• Labeler Name: Swedish Orphan Biovitrum AB (publ)
• Substance Name: EMAPALUMAB
• Active Ingredient Strength: 100 mg/20mL
• Pharm Classes: Interferon gamma Blocker [EPC],Interferon gamma Antagonists [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 66658-510-01

1 VIAL, SINGLE-USE in 1 CARTON (66658-510-01) > 20 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2020-06-26
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "GAMIFANT" or generic name "(emapalumab-lzsg)"

NDC	Brand Name	Generic Name
66658-501	GAMIFANT	(emapalumab-lzsg)
66658-505	GAMIFANT	(emapalumab-lzsg)
66658-510	GAMIFANT	(emapalumab-lzsg)
72171-501	GAMIFANT	(emapalumab-lzsg)
72171-505	GAMIFANT	(emapalumab-lzsg)